Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
![AI](https://streamlined.nyc3.cdn.digitaloceanspaces.com/assets/ai-default.gif)
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about AbbVie Inc.
AbbVie Inc. News
AbbVie Inc. Quantitative Score
![Website screenshot](https://streamlined.nyc3.cdn.digitaloceanspaces.com/website-screenshots/abbvie-com.webp)
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. Earnings & Revenue
AbbVie Inc. Financials
Table Compare
Compare ABBV metrics with: | |||
---|---|---|---|
Earnings & Growth | ABBV | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ABBV | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ABBV | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ABBV | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
AbbVie Inc. Income
AbbVie Inc. Balance Sheet
AbbVie Inc. Cash Flow
AbbVie Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
AbbVie Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 6.1300 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-08-15 | 1.55 | Quarterly |
2024-05-15 | 1.55 | Quarterly |
2024-02-15 | 1.55 | Quarterly |
2023-11-15 | 1.48 | Quarterly |
2023-08-15 | 1.48 | Quarterly |
Historical Market Cap
Shares Outstanding
AbbVie Inc. Executives
Name | Role |
---|---|
Mr. Richard A. Gonzalez | Executive Chairman |
Mr. Robert A. Michael | Chief Executive Officer & Director |
Mr. Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer |
Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President & Chief Operating Officer |
Mr. Scott T. Reents | Executive Vice President & Chief Financial Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Richard A. Gonzalez | Executive Chairman | Male | 1954 | 7.19M |
Mr. Robert A. Michael | Chief Executive Officer & Director | Male | 1970 | 4.62M |
Mr. Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer | Male | 1969 | 4.32M |
Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President & Chief Operating Officer | 1963 | 3.51M | |
Mr. Scott T. Reents | Executive Vice President & Chief Financial Officer | Male | 1968 | 3.13M |
AbbVie Inc. Insider Trades
Date | 17 Jul |
Name | GONZALEZ RICHARD A |
Role | EXECUTIVE CHAIRMAN OF BOARD |
Transaction | Acquired |
Type | M-Exempt |
Shares | 87050 |
Date | 17 Jul |
Name | GONZALEZ RICHARD A |
Role | EXECUTIVE CHAIRMAN OF BOARD |
Transaction | Acquired |
Type | M-Exempt |
Shares | 119418 |
Date | 17 Jul |
Name | GONZALEZ RICHARD A |
Role | EXECUTIVE CHAIRMAN OF BOARD |
Transaction | Acquired |
Type | M-Exempt |
Shares | 76377 |
Date | 17 Jul |
Name | GONZALEZ RICHARD A |
Role | EXECUTIVE CHAIRMAN OF BOARD |
Transaction | Disposed |
Type | S-Sale |
Shares | 282845 |
Date | 17 Jul |
Name | GONZALEZ RICHARD A |
Role | EXECUTIVE CHAIRMAN OF BOARD |
Transaction | Disposed |
Type | M-Exempt |
Shares | 87050 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
17 Jul | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | Acquired | M-Exempt | 87050 |
17 Jul | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | Acquired | M-Exempt | 119418 |
17 Jul | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | Acquired | M-Exempt | 76377 |
17 Jul | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | Disposed | S-Sale | 282845 |
17 Jul | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | Disposed | M-Exempt | 87050 |